Head to Head Comparison: CorMedix (NASDAQ:CRMD) and Entero Therapeutics (NASDAQ:ENTO)

CorMedix (NASDAQ:CRMD) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.

Analyst Ratings

This is a summary of recent ratings and price targets for CorMedix and Entero Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0	2	6	2	3.00
Entero Therapeutics	1	0	0	0	1.00

CorMedix currently has a consensus target price of $18.83, indicating a potential upside of 62.08%. Given CorMedix’s stronger consensus rating and higher probable upside, equities research analysts plainly believe CorMedix is more favorable than Entero Therapeutics.

Profitability

This table compares CorMedix and Entero Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CorMedix	42.11%	42.73%	34.19%
Entero Therapeutics	N/A	-1,063.82%	-17.94%

Earnings & Valuation

This table compares CorMedix and Entero Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$43.47 million	20.94	-$17.93 million	$0.75	15.49
Entero Therapeutics	N/A	N/A	-$18.06 million	($2.37)	-1.87

CorMedix has higher revenue and earnings than Entero Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

CorMedix has a beta of 1.85, meaning that its share price is 85% more volatile than the S&P 500. Comparatively, Entero Therapeutics has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500.

Insider and Institutional Ownership

34.2% of CorMedix shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 5.3% of CorMedix shares are owned by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

CorMedix beats Entero Therapeutics on 14 of the 14 factors compared between the two stocks.

About CorMedix

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

About Entero Therapeutics

Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.